Company · Healthcare
Australian technology used to treat Actinic Keratosis
Melbourne, VIC
Every investor coverage indicates participated in a round Peplin Inc raised.
The transaction that ended Peplin Inc's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| LEO Pharma A/S | Acquisition | 3 Sep 2009 | ~$348.4m | GBS Ventures (3 Sep 2009), GBS Ventures (3 Sep 2009) |
Companies Peplin Inc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Joshua Funder | Director (former) | GBS Ventures (3 Sep 2009), GBS Ventures (18 Aug 2008) |
| Tom Wiggans | Chairman and CEO | GBS Ventures (3 Sep 2009), GBS Ventures (19 May 2009), GBS Ventures (18 Aug 2008) |
Stories naming Peplin Inc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
Leo Pharma has agreed a US$287.5m cash takeover of Peplin, the ASX-listed skin-disease drug developer in GBS Ventures' portfolio; GBS recalls leading its late-2008 round alongside two American venture backers.
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.
Also GBS Ventures
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
ASX-listed biotech Peplin arranged a private placement of roughly US$24 million to advance its keratosis drug into Phase III testing, led by GBS Venture Partners with several existing shareholders also taking part.